false 0001723059 0001723059 2024-08-05 2024-08-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K/A

 

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

August 5, 2024

(Date of Report)

 

August 9, 2024

(Date of Amendment)

 

BIO ESSENCE CORP.

(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)

 

California   333-232839   94-3349551

(STATE OR OTHER JURISDICTION OF

INCORPORATION OR ORGANIZATION)

   (COMMISSION FILE NO.)   (IRS EMPLOYEE
IDENTIFICATION NO.)

 

12 Chrysler, Unit B, Irvine, CA 92618
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

 

(949) 706-9966
(ISSUER TELEPHONE NUMBER)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter. ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

SECTION 4 – MATTERS RELATED TO ACCOUNTANTS AND FINANCIAL STATEMENTS

 

Item 4.01 Changes om Registrant’s Certifying Accountant

 

On August 1, 2024, Bio Essence Corp., a California corporation (the “Company”) dismissed its prior independent accountant, Keith K. Zhen, CPA. The prior financial statements for the past two years do not contain any adverse opinion or disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope, or accounting principles. The decision to change auditors and dismiss Keith K. Zhen, CPA, was reviewed and recommended by the Board of Directors, but not formally approved. During the last two fiscal years, the Company did not have any disagreements with the former accountant on any matter of accounting principles or practices, financial statement disclosure, or auditing score or procedure. No further disclosures are required under Section 304(a)(1)(v) of Regulation S-K. A copy of this Current Report on Form 8-K has been furnished to Keith K. Zhen, CPA, and the Company has requested that Keith K. Zhen, CPA provide a letter addressed to the U.S. Securities and Exchange Commission (“Commission”) providing the information required by Section 304(c) of Regulation S-K, and upon receipt of the same, the Company shall it with the Commission.

 

Also on August 1, 2024, the Company retained Simon & Edward, LLP (“S&E”) to serve as the Company’s principal accountant to audit the Company’s financial statements. S&E will begin working with the Company immediately, finalizing the second quarter financials for the 2024 fiscal year.

 

On August 7, 2024, the Company’s former independent accountant, Keith K. Zhen, CPA, provided correspondence confirming agreement with the disclosure herein. That letter is attached hereto as an Exhibit.

 

Item 9.01 Financial Statements and Exhibits.

 

Exhibit No.   Description
99.1   Letter from Former Auditor
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BIO ESSENCE CORP.
   
  /s/ Yin Yan
  By: Yin Yan
  Its: Chief Executive Officer
     
  Dated:  August 5, 2024

 

 

2

 

 

Exhibit 99.1

 

 

August 5, 2024

 

U.S. Securities and Exchange Commission

Office of the Chief Accountant

100 F Street, NE

Washington, D.C. 20549

 

Re: Bio Essence Corp.

 

Ladies and Gentlemen:

 

We have read the statements in the Form 8-K, dated August 5, 2024 of Bio Essence Corp. (the “Registrant”) and we agree with such statements therein as related to our firm. We have no basis to and, therefore, do not agree or disagree with the other statements made by the Registrant in the Form 8-K.

 

Very truly yours,

 

/s/ Keith K Zhen CPA  
   
Brooklyn, New York  

 

 

v3.24.2.u1
Cover
Aug. 05, 2024
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag false
Document Period End Date Aug. 05, 2024
Entity File Number 333-232839
Entity Registrant Name BIO ESSENCE CORP.
Entity Central Index Key 0001723059
Entity Tax Identification Number 94-3349551
Entity Incorporation, State or Country Code CA
Entity Address, Address Line One 12 Chrysler
Entity Address, Address Line Two Unit B
Entity Address, City or Town Irvine
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92618
City Area Code 949
Local Phone Number 706-9966
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Bio Essence (PK) (USOTC:BIOE)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024 Click aqui para mais gráficos Bio Essence (PK).
Bio Essence (PK) (USOTC:BIOE)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024 Click aqui para mais gráficos Bio Essence (PK).